Search Results

You are looking at 91 - 100 of 480 items for :

  • "paclitaxel" x
  • Refine by Access: All x
Clear All
Full access

Gastric and Esophageal Cancers: Guidelines Updates

Presented by: Crystal S. Denlinger, Kristina A. Matkowskyj, and Mary F. Mulcahy

treatment options now exist that come on the heels of several negative phase II studies: the TyTAN trial of paclitaxel + lapatinib, 6 the GATSBY trial of trastuzumab emtansine (T-DM1) versus a taxane, 7 and the T-ACT trial of paclitaxel + trastuzumab. 8

Full access

Role of Immunotherapy in Triple-Negative Breast Cancer

Tanya E. Keenan and Sara M. Tolaney

atezolizumab and nab-paclitaxel (NCT01375842) showed a promising ORR of 39.4% in 33 patients, also treated with 0 to 2 prior lines, 27 perhaps related to the ability of taxanes to promote toll-like receptor activity and dendritic cell activation. 28 The

Full access

Chemo- and Radiotherapy in Adjuvant Management of Optimally Debulked Endometrial Cancer

David Scott Miller, Gini Fleming, and Marcus E. Randall

paclitaxel: a Gynecologic Oncology Group study . Gynecol Oncol 2009 ; 112 : 543 – 552 . 13 Fleming GF Brunetto VL Cella D . Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial

Full access

Practicing What We Preach!

Robert J. Morgan Jr

improvement in OS with less toxicity, because by the time it was published paclitaxel had already been proven to be a superior second agent, and the oncology community felt that intraperitoneal chemotherapy was not necessary in the age of the taxanes. Annual

Full access

Lessons From Adaptive Randomization: Spying the I-SPY2 Trial in Breast Cancer

Bishal Gyawali and Saroj Niraula

.gov identifier: NCT01042379 ). The arms consist of one common control arm of standard neoadjuvant chemotherapy with paclitaxel (with an alternate control arm of paclitaxel + trastuzumab or pertuzumab + trastuzumab if HER2-positive) against which other

Full access

Oncology Research Program

scientific peer-review process and are overseen by the ORP. NCCN-sponsored studies funded through the grant mechanism are highlighted below. A Phase I/II Study of Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy Followed by Standard

Full access

NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019

Featured Updates to the NCCN Guidelines

Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum-Gamez, Lisa Barroilhet, Kian Behbakht, Andrew Berchuck, Jonathan S. Berek, Lee-may Chen, Mihaela Cristea, Marie DeRosa, Adam C. ElNaggar, David M. Gershenson, Heidi J. Gray, Ardeshir Hakam, Angela Jain, Carolyn Johnston, Charles A. Leath III, Joyce Liu, Haider Mahdi, Daniela Matei, Michael McHale, Karen McLean, David M. O’Malley, Richard T. Penson, Sanja Percac-Lima, Elena Ratner, Steven W. Remmenga, Paul Sabbatini, Theresa L. Werner, Emese Zsiros, Jennifer L. Burns, and Anita M. Engh

NACT Several prospective trials have explored whether adding bevacizumab to platinum-based regimens improves outcomes for patients treated with NACT. Preliminary results from GEICO 1205/NOVA found that adding bevacizumab to a standard carboplatin/paclitaxel

Full access

NCCN Task Force Report: Management of Neuropathy in Cancer

Michael D. Stubblefield, Harold J. Burstein, Allen W. Burton, Christian M. Custodio, Gary E. Deng, Maria Ho, Larry Junck, G. Stephen Morris, Judith A. Paice, Sudhakar Tummala, and Jamie H. Von Roenn

. Available at: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=4325#nlm34084-4 . Accessed: July 1, 2009 . 10 Ozols RF Bundy BN Greer BE . Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with

Full access

NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022

Featured Updates to the NCCN Guidelines

Deborah K. Armstrong, Ronald D. Alvarez, Floor J. Backes, Jamie N. Bakkum-Gamez, Lisa Barroilhet, Kian Behbakht, Andrew Berchuck, Lee-may Chen, Viola C. Chitiyo, Mihaela Cristea, Maria DeRosa, Eric L. Eisenhauer, David M. Gershenson, Heidi J. Gray, Rachel Grisham, Ardeshir Hakam, Angela Jain, Amer Karam, Gottfried E. Konecny, Charles A. Leath III, Gary Leiserowitz, Joyce Liu, Lainie Martin, Daniela Matei, Michael McHale, Karen McLean, David S. Miller, Sanja Percac-Lima, Steven W. Remmenga, John Schorge, Daphne Stewart, Premal H. Thaker, Roberto Vargas, Andrea Wahner Hendrickson, Theresa L. Werner, Emese Zsiros, Mary A. Dwyer, and Lisa Hang

epithelial cancer types and stage I disease, first-line systemic therapy generally consists of intravenous platinum-based chemotherapy, with the guidelines recommending paclitaxel at 175 mg/m 2 + carboplatin at an area under the curve (AUC) of 5 to 6 every 3

Full access

Novel Approaches to Advanced Breast Cancer: Bevacizumab and Lapatinib

Erica L. Mayer, Nancy U. Lin, and Harold J. Burstein

metastatic colorectal cancer . N Engl J Med 2004 ; 350 : 2335 – 2342 . 12. Sandler A Gray R Brahmer J . Randomized phase II/III Trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced